OCT

New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

Retrieved on: 
Thursday, October 19, 2023
MLA, Effectiveness, Calcification, Dystrophic calcification, Treatment, Prevalence, Publication, Safety, Fracture, IVL, Doctor of Philosophy, PCI, Overalls, Collection, OCT, Disrupt, Atherectomy, Calcium, Bias, Cardiovascular disease, Saint Francis Memorial Hospital, Dietary supplement, MD

The publications each reported separate patient-level pooled optical coherence tomography (OCT) sub-analyses of the company-sponsored Disrupt CAD clinical studies.

Key Points: 
  • The publications each reported separate patient-level pooled optical coherence tomography (OCT) sub-analyses of the company-sponsored Disrupt CAD clinical studies.
  • “While the majority of the robust, core-lab adjudicated evidence supporting coronary IVL to date has studied concentric calcium, we are beginning to see a shift in evidence reinforcing IVL use across all calcium morphologies, both in retrospective analyses and ‘real-world’ prospective registries,” said Keith D. Dawkins, MD, Chief Medical Officer of Shockwave Medical.
  • While there were no differences in pre-procedure minimum lumen area (MLA), diameter stenosis, or maximum calcium thickness across the different calcium arcs, the calcium length and overall volume index increased progressively with concentric calcium, and a higher minimum calcium thickness was increased with eccentric calcium.
  • “Given the relatively low prevalence of nodules, it has been challenging to perform large prospective controlled studies.

Heidelberg Engineering Announces FDA Clearance for All-in-One ANTERION Platform

Retrieved on: 
Friday, October 13, 2023
Apps, Applications, Technology, Medical Devices, FDA, Health Technology, Software, Biotechnology, Hardware, Health, Optical, Diagnosis, Multimedia, Lumia imaging apps, Acquisition, Corneal topography, Aqueous humour, OD, OCT, Clinical trial, Cataract, Heidelberg, IOL, Tomography, Cornea, Medical device, Medical imaging, Telescopic sight

Heidelberg Engineering , a global leader in ophthalmic imaging and healthcare data solutions, announces FDA clearance of its innovative all-in-one ANTERION® platform , designed to transform anterior segment diagnostics and streamline practice workflow.

Key Points: 
  • Heidelberg Engineering , a global leader in ophthalmic imaging and healthcare data solutions, announces FDA clearance of its innovative all-in-one ANTERION® platform , designed to transform anterior segment diagnostics and streamline practice workflow.
  • View the full release here: https://www.businesswire.com/news/home/20231013216160/en/
    “Building upon our previous CE-marking, we are thrilled that the ANTERION platform is now available to eye care providers across the U.S.,” said Arianna Schoess Vargas, Managing Director of Heidelberg Engineering GmbH.
  • Central to the ANTERION platform is the Imaging App, which was FDA cleared in November 2021.
  • For more information about ANTERION, visit our website or contact us directly.

Elixir Medical To Present Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus at TCT 2023

Retrieved on: 
Thursday, October 5, 2023
Science, Cardiology, Biotechnology, Research, Health, Medical Devices, Health Technology, Clinical Trials, Elixir, Exhibition, Death, Medicine, Innovation, Coronary artery disease, DAPT, Risk, Moscone Center, PCI, Anticoagulant, Percutaneous coronary intervention, Data collection, Abstract (summary), Novel, OCT, Clinical study design, Automotive Supplier Innovation Program, Sirolimus, Rivaroxaban, Patient, RCT, Diagnosis, TCT, Pharmaceutical industry, Fine chemical

The data compare DESyne BDS Plus, the world’s first triple drug-eluting stent with local anticoagulation delivery technology using two anticoagulants (rivaroxaban and argatroban) and an anti-proliferative mTOR inhibitor (sirolimus) to a second-generation durable polymer DES.

Key Points: 
  • The data compare DESyne BDS Plus, the world’s first triple drug-eluting stent with local anticoagulation delivery technology using two anticoagulants (rivaroxaban and argatroban) and an anti-proliferative mTOR inhibitor (sirolimus) to a second-generation durable polymer DES.
  • “Stent thrombosis after percutaneous coronary intervention (PCI), though rare, is a severe complication with death or heart attack risk of up to 50% after the event.
  • An imaging subset of 60 patients had angiographic and optical coherence tomography (OCT) assessment completed at six months.
  • Elixir Medical is also hosting the scientific symposium, “Innovation for PCI: Improved outcomes require disruption” featuring a panel of speakers including Robert W. Yeh, M.D., Mirvat Alasnag, M.D, Ignacio Cruz-Gonzalez, M.D., Ph.D., Roxana Mehran, M.D.

RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Retrieved on: 
Thursday, October 5, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Congress, Lineage Cell Therapeutics, Tel Aviv Sourasky Medical Center, Letter, Trial of the century, Cell, Maintenance, OPL, OCT, Therapy, AMD, NYSE American, GA, INL, TASE, RPE, Patient, Geographic atrophy, ELM, Fine chemical, Medical imaging, Genentech, Ophthalmology, Lineage

RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

Key Points: 
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.
  • “We are extremely pleased to see these additional observations of rapid improvements to outer retinal structure in the initial clinical study of OpRegen.
  • Durability of retinal structure improvements beyond the 12-month primary endpoint is still being evaluated in other patients.

75% of Vision Loss Is Preventable and Treatable, but Half of Canadians Don't Know It

Retrieved on: 
Thursday, October 12, 2023
Paratriathlon, Family, Eye, World Sight Day, Diabetic retinopathy, Specsavers, OCT, Glaucoma, Optometry, Optical coherence tomography, Survey, Nursing, Telescopic sight

"The survey showed that most Canadians are unaware that most vision loss is preventable and treatable.

Key Points: 
  • "The survey showed that most Canadians are unaware that most vision loss is preventable and treatable.
  • The Survey showed over one-third of Canadians (35 per cent) would only book an eye exam if they experienced vision issues.
  • Catching eye diseases early through a comprehensive eye exam allows for preventative measures to maintain as much vision as possible.
  • What many don't know is that often eye diseases, such as glaucoma, progress without symptoms in the early stages.

Optical Coherence Tomography (OCT) Market to Grow Significantly by 2029- Brandessence Market Research

Retrieved on: 
Wednesday, October 4, 2023
Optical coherence tomography, Ageing, Research, Science, Algorithm, OCT, Ophthalmology, Artificial intelligence, Growth, AI, BioScience Research Collaborative, Aroma compound, Medical device, Medical imaging, Pharmaceutical industry

Key reports include:

Key Points: 
  • Key reports include:
    "Global Optical Coherence Tomography Market Report": This report provides a comprehensive overview of the market, including market size, growth trends, and competitive analysis.
  • Research Collaborations: Collaborations between research institutions and healthcare providers can drive innovation and expand the market.
  • The Optical Coherence Tomography (OCT) market is on an upward trajectory, driven by the demand for non-invasive diagnostics, technological advancements, and the aging population.
  • As the OCT market continues to evolve, it promises to play a pivotal role in revolutionizing medical diagnostics and research across various domains.

Optical Coherence Tomography (OCT) Market to Grow Significantly by 2029- Brandessence Market Research

Retrieved on: 
Wednesday, October 4, 2023
Optical coherence tomography, Ageing, Research, Science, Algorithm, OCT, Ophthalmology, Artificial intelligence, Growth, AI, BioScience Research Collaborative, Aroma compound, Medical device, Medical imaging, Pharmaceutical industry

Key reports include:

Key Points: 
  • Key reports include:
    "Global Optical Coherence Tomography Market Report": This report provides a comprehensive overview of the market, including market size, growth trends, and competitive analysis.
  • Research Collaborations: Collaborations between research institutions and healthcare providers can drive innovation and expand the market.
  • The Optical Coherence Tomography (OCT) market is on an upward trajectory, driven by the demand for non-invasive diagnostics, technological advancements, and the aging population.
  • As the OCT market continues to evolve, it promises to play a pivotal role in revolutionizing medical diagnostics and research across various domains.

EQS-News: Mynaric passes major product milestone of CONDOR Mk3, completing verification and interoperability tests

Retrieved on: 
Thursday, September 28, 2023
CONDOR, SDA, United States Naval Research Laboratory, Tranche, Space Development Agency, FRA, Acquisition, OCT, Printed circuit board, Mynaric

Mynaric passes major product milestone of CONDOR Mk3, completing verification and interoperability tests

Key Points: 
  • Mynaric passes major product milestone of CONDOR Mk3, completing verification and interoperability tests
    The issuer is solely responsible for the content of this announcement.
  • MUNICH, September 28, 2023 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced an important product milestone of its CONDOR Mk3 optical communications terminals.
  • Mynaric will supply the CONDOR Mk3 terminals to Northrop Grumman’s satellites for the Tranche 1 Transport and Tracking Layer programs .
  • Subsequent optical interoperability tests, conducted at the Naval Research Lab , successfully demonstrated the product’s capability to optically interconnect with terminals from other vendors.

LumiThera Receives Notice of Award for National Eye Institute Grant to Support a 3rd Year Extension to LIGHTSITE III, the U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration

Retrieved on: 
Wednesday, September 27, 2023
Professional Services, Medical Devices, Health, Small Business, Clinical Trials, Optical, Retina, Small business, Vance DeGeneres, NEI, AMD, SBIR, Duke University School of Medicine, Geographic atrophy, Intravitreal injection, GA, Ophthalmology, HIV disease progression rates, Patient, National Eye Institute, OCT, PBM, Knowledge, NIH, National Institutes of Health Clinical Center, Disease, Pharmaceutical industry

The NIH/NEI grant supports an open-label human clinical trial in U.S. intermediate dry age-related macular degeneration (dry AMD) subjects that participated in the pivotal LIGHTSITE III trial.

Key Points: 
  • The NIH/NEI grant supports an open-label human clinical trial in U.S. intermediate dry age-related macular degeneration (dry AMD) subjects that participated in the pivotal LIGHTSITE III trial.
  • LIGHTSITE IIIB will treat patients for 4 rounds of treatment over fourteen months.
  • Sham patients in the previous study will be able to cross over and begin PBM treatment.
  • “We are excited to have the NIH/NEI partially support the further development endeavors of LumiThera as we bring the therapy to U.S. patients.”

CACI Successfully Completes Optical Communications Terminal Interoperability Testing for Space Development Agency’s Transport Layer

Retrieved on: 
Monday, September 18, 2023
Technology, Contracts, Security, Engineering, Aerospace, Software, Manufacturing, Networks, Government Technology, Defense, OIT, Communication, SDA, Human, Interoperability, CACI, Architecture, Lexmark International, Inc. v. Static Control Components, Inc., OCT, Beam, Innovative Solutions In Space, NYSE, Communications satellite

CACI International Inc ( NYSE: CACI ) announced today that it successfully completed Optical Communication Terminal (OCT) Interoperability Testing (OIT) of its CrossBeam® OCT for the Space Development Agency’s (SDA) Tranche 1 data relay and tracking network.

Key Points: 
  • CACI International Inc ( NYSE: CACI ) announced today that it successfully completed Optical Communication Terminal (OCT) Interoperability Testing (OIT) of its CrossBeam® OCT for the Space Development Agency’s (SDA) Tranche 1 data relay and tracking network.
  • As part of this testing, CACI was the first SDA-compliant terminal to successfully establish a consistent data communication link with the reference modem.
  • “Our proven, mature, and low-risk technology, combined with our advancements in scalable, U.S.-based manufacturing capacity, will rapidly transform sensing and communications for national security missions,” said Todd Probert , President of National Security and Innovative Solutions at CACI.
  • This successful testing demonstrates performance to the version 3.0 standard and allows the CrossBeam OCT to move forward with OIT with optical payloads, thereby verifying interoperability in support of SDA’s Proliferated Warfighter Space Architecture constellation of tracking and transport satellites.